Rsv Disease

Routine childhood immunizations have prevented 1.1 million deaths in the United States since the CDC’s Vaccines for Children program launched in 1994, according to researchers.

The FDA accepted a biologics license application for Merck’s respiratory syncytial virus immunization, clesrovimab, the company announced Tuesday.

The bivalent respiratory syncytial virus prefusion F, or RSVpreF, vaccine may prevent one hospitalization or ED visit tied to the infection for every 250 vaccinated older adults, an analysis showed.

Nirsevimab and the maternal vaccine for respiratory syncytial virus can reduce health care costs and productivity losses associated with RSV but lead to higher overall spending, according to analyses published in Pediatrics.

Another monoclonal antibody for preventing respiratory syncytial virus disease in infants could enter the market as early as next year, based on the results of two studies presented at IDWeek, Merck said.

In a large cohort of adults who underwent surgery, nasal colonization with Staphylococcus aureus accounted for most postoperative staph infections, according to a study published in Open Forum Infectious Diseases.